Novel opioid could provide pain relief alternative to fentanyl
NFEPP, a new opioid, inhibited colon pain in mice with colitis but did not cause the side effects associated with use of fentanyl.
List view / Grid view
NFEPP, a new opioid, inhibited colon pain in mice with colitis but did not cause the side effects associated with use of fentanyl.
A combination of checkpoint and small molecule inhibitors showed success at targeting Myc oncogenes in mouse neuroblastoma and melanoma models.
An assay that combines 3D disease models and automated AI-based fibrosis quantification could accelerate NASH drug discovery.
A drug called topotecan (TPT) was administered to mice up to four days after COVID-19 infection, reducing inflammation and morbidity.
A novel artificial intelligence (AI) technique called ProteinGAN has shown success at studying well known proteins to develop new ones.
Researchers have shown that prime editing is able to effectively edit genes in mice but without the off-target effects of CRISPR.
Researchers have revealed that T cells in blood samples from people who recovered from COVID-19 responded to SARS-CoV-2 variants.
Researchers have created a single-celled synthetic organism able to grow and divide that could be used to produce drugs and detect disease.
A new hydrogel has been shown to convert cancer cells to cancer stem cells within 24 hours, in six different human cancer cell line types.
Researchers have used imaging mass cytometry to analyse the cellular landscape of diseased lung tissue in severe COVID-19, revealing insights into the disease.
A mAb could be used in tooth regeneration therapy, after a single administration generated new teeth in mice and ferrets.
A new delivery vector using platelets has shown success in pre-clinical trials at delivering photothermal particles and immunostimulators to tumours.
A study has revealed that blocking a molecule called IRE1α could prevent the release of neutrophil extracellular traps in lupus pathogenesis.
An aptamer that can bind a different part of SARS-CoV-2 than known inhibitors could enhance treatments against coronavirus mutations.
Researchers have revealed that the protein ALYREF promotes the effects of the neuroblastoma gene, MYCN, making it a target.